1. Home
  2. AMPH vs DVAX Comparison

AMPH vs DVAX Comparison

Compare AMPH & DVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AMPH
  • DVAX
  • Stock Information
  • Founded
  • AMPH 1996
  • DVAX 1996
  • Country
  • AMPH United States
  • DVAX United States
  • Employees
  • AMPH N/A
  • DVAX N/A
  • Industry
  • AMPH Biotechnology: Pharmaceutical Preparations
  • DVAX Biotechnology: Pharmaceutical Preparations
  • Sector
  • AMPH Health Care
  • DVAX Health Care
  • Exchange
  • AMPH Nasdaq
  • DVAX Nasdaq
  • Market Cap
  • AMPH 1.1B
  • DVAX 1.3B
  • IPO Year
  • AMPH 2014
  • DVAX 2004
  • Fundamental
  • Price
  • AMPH $30.50
  • DVAX $10.50
  • Analyst Decision
  • AMPH Buy
  • DVAX Buy
  • Analyst Count
  • AMPH 5
  • DVAX 4
  • Target Price
  • AMPH $36.20
  • DVAX $26.50
  • AVG Volume (30 Days)
  • AMPH 641.0K
  • DVAX 1.5M
  • Earning Date
  • AMPH 08-07-2025
  • DVAX 08-07-2025
  • Dividend Yield
  • AMPH N/A
  • DVAX N/A
  • EPS Growth
  • AMPH N/A
  • DVAX N/A
  • EPS
  • AMPH 2.68
  • DVAX N/A
  • Revenue
  • AMPH $722,679,000.00
  • DVAX $316,268,000.00
  • Revenue This Year
  • AMPH $1.06
  • DVAX $23.23
  • Revenue Next Year
  • AMPH $7.06
  • DVAX $16.57
  • P/E Ratio
  • AMPH $11.38
  • DVAX N/A
  • Revenue Growth
  • AMPH 1.37
  • DVAX 26.66
  • 52 Week Low
  • AMPH $20.39
  • DVAX $9.22
  • 52 Week High
  • AMPH $53.96
  • DVAX $14.63
  • Technical
  • Relative Strength Index (RSI)
  • AMPH 74.11
  • DVAX 45.80
  • Support Level
  • AMPH $29.42
  • DVAX $10.28
  • Resistance Level
  • AMPH $30.99
  • DVAX $11.45
  • Average True Range (ATR)
  • AMPH 1.31
  • DVAX 0.46
  • MACD
  • AMPH 0.51
  • DVAX -0.05
  • Stochastic Oscillator
  • AMPH 93.07
  • DVAX 29.09

About AMPH Amphastar Pharmaceuticals Inc.

Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

Share on Social Networks: